Petlife Pharmaceuticals, Inc.
Petlife Pharmaceuticals, Inc.
Your view on PTLF
Overview
What the company does, where it operates, and who runs it.
About Petlife Pharmaceuticals, Inc.
- Industry
- Drug Manufacturers - Specialty & Generic
- Sector
- Healthcare
- CEO
- Sebastian Serrell-Watts
- Headquarters
- 8033 Sunset Boulevard, Los Angeles, CA, US
- Industry
- Drug Manufacturers - Specialty & Generic
- Sector
- Healthcare
- CEO
- Sebastian Serrell-Watts
- Headquarters
- 8033 Sunset Boulevard, Los Angeles, CA, US
Petlife Pharmaceuticals, Inc. engages in the research, development, sale, and support of drugs and nutraceuticals for pet cancer and autoimmune related diseases, such as arthritis in the United States. The company's principal product is Vitalzul that inhibits blood vessels formation in solid tumors.
It is also developing Vitalzul as a prescription strength oral pharmaceutical, as well as a concentrated intravenous and injectable version for direct administration to a tumor. In addition, the company develops edible dog and cat treats. Petlife Pharmaceuticals, Inc. is based in Los Angeles, California.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for Petlife Pharmaceuticals, Inc., and the rating behind it. PTLF last traded at $0.0001; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Petlife Pharmaceuticals, Inc.. Starting points for Petlife Pharmaceuticals, Inc.: EPS -$0.34, beta 3.91 — an Drug Manufacturers - Specialty & Generic name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Petlife Pharmaceuticals, Inc.. Petlife Pharmaceuticals, Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Petlife Pharmaceuticals, Inc.. Trailing twelve-month EPS for Petlife Pharmaceuticals, Inc. stands at -$0.34. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Petlife Pharmaceuticals, Inc.. Petlife Pharmaceuticals, Inc. has reported as a listed company since 2008. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Petlife Pharmaceuticals, Inc. valued side by side against its closest peers. Petlife Pharmaceuticals, Inc. is measured against Drug Manufacturers - Specialty & Generic peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold Petlife Pharmaceuticals, Inc., and how their positions are changing. At a $19,675 market value, institutional positions materially move Petlife Pharmaceuticals, Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by Petlife Pharmaceuticals, Inc. executives and directors. Shares of Petlife Pharmaceuticals, Inc. have traded between $0.0001 and $0.0010 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Petlife Pharmaceuticals, Inc.. Petlife Pharmaceuticals, Inc. is a $19,675 Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Petlife Pharmaceuticals, Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Petlife Pharmaceuticals, Inc.. Coverage tracks Petlife Pharmaceuticals, Inc. within Drug Manufacturers - Specialty & Generic (Healthcare). Press releases and market coverage, newest first.